The Rising Prevalence Of Hodgkin Lymphoma And Increasing Awareness Regarding Hodgkin Lymphoma To Boost The Hodgkin Lymphoma Treatment Market Growth

Hodgkin Lymphoma Treatment Market
Hodgkin Lymphoma Treatment Market

The Hodgkin Lymphoma Treatment Market is Segmented by Treatment Type (Chemotherapy, Radiotherapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Size, Share, Outlook, and Opportunity Analysis, 2023-2030

The global Hodgkin Lymphoma Treatment Market is estimated to be valued at reach US$ 15.8 Billion by 2030 and is expected to exhibit a CAGR of 8.4 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

The major treatment for Hodgkin lymphoma is chemotherapy, or chemotherapy and the radiotherapy. Rarely, chemotherapy may be coupled with steroid drugs. Some patients also have biological drugs. Operation isn't usually utilized to cure the problem, excluding the biopsy utilized to analyze it.

Competitive Landscape:

Key players involved in the growth of the global Hodgkin Lymphoma Treatment Market are Biogen Inc., Incyte Corp, Alkem Laboratories, F Hoffmann-La Roche Ltd, Amneal Pharmaceuticals, Inc., Merck & Co. Inc., Seagen Inc., Baxter International Inc., Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Ltd.

Market Key Drivers:

The rising prevalence of Hodgkin lymphoma and increasing awareness regarding Hodgkin Lymphoma is expected to augment the growth of the global Hodgkin lymphoma treatment for market. For instance, as per the ACS around 8,540 people suffer from Hodgkin Lymphoma in U.S.

Various research survey on the efficiency of better therapeutics have been performed and are enhancing the awareness associated to the disorders and their therapeutics is projected to propel the growth of global Hodgkin Lymphoma Treatment Market. For instance, in June 2022, a research survey was published named Brentuximab vedotin and linked with event-free survival in kids with recently analyzed high-threat Hodgkin lymphoma.

Competitive Landscape:

The COVID-19 outbreak was projected to have a significant effect on the growth of global Hodgkin lymphoma treatment for market due to the global spread of the COVID-19 pandemic, the market's growth reduced drastically. Along with the public health restrictions of the COVID-19, there was a delay and interruption of surgical services across the globe, which had severe effects for patients with medical problems and surgical facilities.

The rising regulatory body approval of pharmaceutical treatments for the Clostridioides Difficile Infection Treatment Market may be a major factor in the expansion of the market for treating this infection.

Key Takeaways:

The global Hodgkin Lymphoma Treatment Market is anticipated to exhibit a CAGR at higher rate during the forecast period due to rising use of radiotherapy technique for Hodgkin disease. For instance, In June 2020, as per a survey report published in Radiation therapeutics for Advanced-Stage Hodgkin Lymphoma declared that as per the ACS, Hodgkin lymphoma is a rare disorder, with around 8110 new incidences and 1000 deaths due to Hodgkin lymphoma in 2019.

Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the global Hodgkin lymphoma treatment for market due to rising cases of Hodgkin Lymphoma, increasing investments, rising developments. For instance, as per the Globocan 2020 report, around 9,077 new incidences of Hodgkin lymphoma tumor were analyzed in the North American region in 2020 and by 2040, this count is projected to cross 10,346 cases, around 14% rise from 2020.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more